Molecular structure of Entecavir, CAS Number: 142217-69-4
Entecavir (CAS 142217-69-4)
See product citations (11)
Alternate Names:
2-amino-9-[(1S,3R,4S)-4-hydroxy-3-(hydroxymethyl)-2-methylidenecyclopentyl]-3H-purin-6-one
Application:
Entecavir is a guanine analog that inhibits reverse transcription
CAS Number:
142217-69-4
Purity:
≥99%
Molecular Weight:
277.28
Molecular Formula:
C12H15N5O3
For Research Use Only. Not Intended for Diagnostic or Therapeutic Use.
* Refer to Certificate of Analysis for lot specific data.
QUICK LINKS
Ordering Information
Product Citations
Description
Technical Information
Safety Information
SDS & Certificate of Analysis
Entecavir is a deoxyguanosine nucleoside analogue with antiviral activity against the hepatitis B virus (HBV). The compound has a mechanism of action by inhibiting priming and chain extension through inhibition of HBV DNA polymerase. Entecavir is also documented as the most potent HBV DNA polymerase inhibitor and superior to Lamivudine (sc-221830) due to its effectiveness against Lamivudine resistant HBV strains and being 30 fold more active.
Entecavir (CAS 142217-69-4) References
- Entecavir: a potent new antiviral drug for hepatitis B. | Honkoop, P. and De Man, RA. 2003. Expert Opin Investig Drugs. 12: 683-8. PMID: 12665423
- Mechanisms of action of interferon and nucleoside analogues. | Thomas, H., et al. 2003. J Hepatol. 39 Suppl 1: S93-8. PMID: 14708685
- Entecavir: a new treatment option for chronic hepatitis B. | Zoulim, F. 2006. J Clin Virol. 36: 8-12. PMID: 16515882
- Entecavir for the treatment of chronic hepatitis B virus infection. | Matthews, SJ. 2006. Clin Ther. 28: 184-203. PMID: 16678641
- Entecavir: a new nucleoside analog for the treatment of chronic hepatitis B infection. | Sims, KA. and Woodland, AM. 2006. Pharmacotherapy. 26: 1745-57. PMID: 17125436
- Entecavir: a new nucleoside analogue for the treatment of chronic hepatitis B. | Rivkin, A. 2007. Drugs Today (Barc). 43: 201-20. PMID: 17460784
- Entecavir: a potent antiviral with minimal long-term resistance in nucleoside-naive chronic hepatitis B patients. | Cheng, PN. and Chang, TT. 2008. Expert Rev Anti Infect Ther. 6: 569-79. PMID: 18847396
- Entecavir for the treatment of chronic hepatitis B infection. | Shepherd, J., et al. 2009. Health Technol Assess. 13 Suppl 3: 31-6. PMID: 19846026
- Entecavir-associated myopathy: a case report and literature review. | Yuan, K., et al. 2014. Muscle Nerve. 49: 610-4. PMID: 24218312
- An evaluation of entecavir for the treatment of chronic hepatitis B infection in adults. | Lee, HW., et al. 2016. Expert Rev Gastroenterol Hepatol. 10: 177-86. PMID: 26610256
- Effects of Tenofovir vs Entecavir on Risk of Hepatocellular Carcinoma in Patients With Chronic HBV Infection: A Systematic Review and Meta-analysis. | Choi, WM., et al. 2021. Clin Gastroenterol Hepatol. 19: 246-258.e9. PMID: 32407970
- Entecavir versus tenofovir in patients with chronic hepatitis B: Enemies or partners in the prevention of hepatocellular carcinoma. | Lee, SW., et al. 2021. Clin Mol Hepatol. 27: 402-412. PMID: 34157830
- Entecavir-associated thrombocytopenia. | Yu, Y. and Feng, H. 2021. Int J Immunopathol Pharmacol. 35: 20587384211059676. PMID: 34823407
Inhibitor of:
Adenovirus-2 E1A, cadherin-26, CNT1, DGUOK, Gα s, HBV xAg, Hep B cAg, Hep B Pol, NASP, and TMC7.Activator of:
Hep B preS2.Ordering Information
| Product Name | Catalog # | UNIT | Price | Qty | FAVORITES | |
Entecavir, 1 mg | sc-204738 | 1 mg | $77.00 | |||
Entecavir, 5 mg | sc-204738A | 5 mg | $214.00 | |||
Entecavir, 25 mg | sc-204738B | 25 mg | $632.00 |